ascopubs.org

Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.

A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations. This is an ASCO Meeting Abstract from ...
ascopubs.org

Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as first-line treatment for unresectable intrahepatic cholangiocarcinoma: A propensity score ...

Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study). This is an ...
Medscape

Doublet Immunotherapy Disappoints in Gastric Cancer Study

BARCELONA — The combination of standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival compared with chemotherapy alone in patients with HER2-negative gastric ...
Benzinga.com

Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial

On Saturday, Johnson & Johnson (NYSE: JNJ) shared new longer follow-up results from the Phase 1b/2 OrigAMI-1 study. The trial is evaluating Rybrevant (amivantamab-vmjw) in combination with FOLFOX or ...